Introduction {#s1}
============

Pharmacological therapy is a key component of secondary prevention following acute coronary syndrome (ACS). Despite the effectiveness of such therapies, many patients do not follow their regimen as prescribed and are deemed non-adherent. It is estimated that approximately one-third of patients are non-adherent to cardiac medications following ACS.[@R1] Non-adherence among cardiac patients presents a considerable clinical problem because of its association with poor outcomes that include mortality, morbidity and risk of rehospitalisation.[@R2]

Adherence is complex in nature and is driven by a myriad of patient-related (eg, beliefs about treatment), healthcare provider (HCP)-related (eg, communication) and healthcare system-wide factors (eg, treatment cost and access). A recent review of psychosocial factors found that depression and treatment beliefs were predictors of non-adherence following ACS.[@R3] Identifying potentially modifiable factors is crucial for the design and implementation of evidence-based interventions to improve adherence.

There have been multiple attempts to synthesis the evidence base for adherence interventions in chronic disease,[@R4] coronary artery disease (CAD)[@R5] and cardiovascular disease.[@R6] Moreover, there have been numerous reviews looking at interventions targeting adherence to specific medication classes including statins,[@R7] antihypertensives[@R8] and oral antiplatelet therapy.[@R9] HCPs (ie, physicians, nurses, pharmacists) play a key role in supporting, promoting and monitoring adherence for chronic conditions. Previous reviews have reported the benefit of adherence interventions delivered by multiple HCPs,[@R10] pharmacists[@R11] and nurses.[@R5] However, to date, the impact of these types of interventions for patients with ACS has yet to be systematically explored.

Interventions that target behaviours such as medication taking are often complex and comprise multiple components. In order to identify the specific strategies best suited to change specific behaviours, complex interventions need to be compartmentalised. Behaviour change frameworks such as the theoretical domains framework[@R12] and behaviour change technique (BCT) taxonomy[@R13] have been designed to aid this compartmentalisation process through specifying interventions into their 'active content'. These types of models have been used across a range of health behaviours, and there is increasing application within medication adherence research.[@R14]

The primary objective of this systematic review and meta-analysis is to determine the effectiveness of HCP-led interventions to support medication adherence following ACS. Additionally, we aim to examine whether effectiveness is moderated by interventionist, delivery method and having a theory-based design. Finally, we aim use a behaviour change framework to identify the specific techniques used among adherence interventions.

Methodology {#s2}
===========

This review was conducted in accordance of the Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines[@R15] and was registered with PROSPERO (<http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016037706>).

Eligibility criteria {#s2a}
--------------------

Studies were included if they met the following criteria:Participants: adults (\>18 years of age) with a confirmed diagnosis of ACS.Intervention: delivered by HCPs.Comparator: parallel group design where treatment group is compared with a clearly defined control group.Outcome: include a measurement or medication adherence as a primary or secondary outcome.Setting: study group allocation determined by randomisation.

We defined an intervention as being HCP led if the primary method of delivery involved HCPs working therapeutically with patients in person and/or via phone.

Studies infrequently distinguish between the different types of non-adherence; therefore, we used a definition of medication adherence that includes treatment initiation, actual dosing and treatment persistence.[@R16]

Search strategy {#s2b}
---------------

A systematic search of the following electronic databases was conducted: The Cochrane Library, Medline, EMBASE, PsycINFO, Web of Science, International Pharmaceutical Abstracts, Cumulative Index to Nursing and Allied Health Literature and Applied Social Sciences Index and Abstracts. An additional grey literature search was also undertaken: OpenGrey, EthOS, WorldCat---Thesis and Dissertations and ProQuest Dissertations & Theses. Searches were limited to articles written in English with no timespan limits. Reference lists of relevant papers were also searched to identify any additional records.

Our search strategy was informed by previous review studies[@R4] and comprised four search themes: condition; therapy type; adherence; study design (see [table 1](#T1){ref-type="table"}) (for full search strategy, see online [supplementary material 1](#SP1){ref-type="supplementary-material"}).
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###### 

Search themes with example search terms

  Search theme   Examples of search terms
  -------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition      Acute coronary syndrome, myocardial infarction, unstable angina, coronary occlusion, coronary thrombosis
  Therapy type   Treatment, medication, medicine, drug, pharmacotherapy, regimen, prescription, prescribed
  Adherence      Compliance, non-compliance, concordance, adherence, non-adherence, discordance, persistence, non-persistence, discontinuation, drop-out, treatment refusal
  Study design   Random, clinical, control, trial, intervention, outcome, treatment outcome

Data extraction {#s2c}
---------------

Records were imported into bibliographic software (EndNote X7) where duplicates were removed. All records were initially screened based on their title and abstract, and relevant articles were full-text screened using our eligibility criteria. All screening and data extraction was undertaken by a single researcher (JC) with experience conducting evidence syntheses. Two additional researchers (VA & JW) undertook partial screening using the eligibility criteria to validate the study selection and data extraction process. Any disagreements between raters (JC, VA and JW) were resolved by consensus. Data were extracted using a standardised data extraction form based on previous review studies[@R4] (see [table 2](#T2){ref-type="table"}). Where necessary, study authors were contacted directly for additional information. We contacted 10 authors to clarify aspects of their methodology of which 80% responded.

###### 

Data extraction criteria

  Data category                 Specific extraction
  ----------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
  Study details                 Author; title
  Source attributes             Study type; funding details; year of distribution
  Methodological features       Group assignment; allocation concealment; comparator group; blinding; attrition; intention to treat; study period; outcome measurement
  Participant characteristics   Age; gender; ethnicity; diagnosis
  Intervention features         Number of sessions; interventionist; length of delivery; theoretical basis; delivery method; targeting additional health behaviours
  Intervention content          BCTs
  Effect size determinations    Sample size; methods of analysis; means; main effects

BCTs, behaviour change technique.

Risk of bias {#s2d}
------------

Methodological quality was judged using A Cochrane Risk of Bias Assessment Tool (ACROBAT)[@R18] where risk is rated as 'high', 'unclear' or 'low' among six domains of bias (Selection; Performance; Detection; Attrition; Reporting and Other Biases). ACROBAT has been used in previous systematic reviews looking at the effectiveness of adherence interventions.[@R19] Risk of bias was assessed by a single researcher (JC).

Statistical analysis {#s2e}
--------------------

Medication adherence was our target outcome, and the direction of effect was transformed for consistent reporting. Where studies reported adherence across multiple medications the data were pooled to provide an estimate of 'overall adherence'. Effect size estimates are expressed in terms of ORs. Where data were originally expressed as means, standardised mean differences were calculated and then transformed to the OR metric using the probit method.[@R20] These should be interpreted as standardised OR.

Random-effects models comparing HCP-led interventions with control interventions were used based on the assumption that there would be statistical heterogeneity from pooling primary study data. The I^2^ statistic was used to estimate statistical heterogeneity, and Cochrane guidelines were used for interpretation.[@R21] Potential publication bias was determined using funnel plots and Egger's test for small study effects. A critical value of. 1 was used for heterogeneity and small study effects significance testing. A study was deemed to be an outlier where the effect size was outside the pseudo 95% CI in the funnel plot as a means for detecting the potential impact of outliers on the pooled effect size.

Secondary studies (ie, primary study data with alternate end-points) were excluded from meta-analysis so as not to duplicate data. Prespecified subgroup analyses were conducted based on (1) type of interventionist, (2) delivery method and (3) theory-based design. Additional post hoc analyses were done based on adherence outcome and risk of bias. All analyses were done using Stata 14.1.

Coding intervention content {#s2f}
---------------------------

We used the BCT taxonomy[@R13] to identify specific techniques used to change medication-taking behaviour among our intervention studies. The BCT taxonomy comprises 93 unique BCTs categorised into 16 clusters. A BCT is defined as an 'active ingredient' that can be used to alter or redirect behaviour. The BCT taxonomy includes a detailed description of each technique and provides specific examples (eg, 'action planning' (BCT 1.4): *'prompt planning the performance of a particular physical activity at a particular time on certain days of the week'* (the numbers in parentheses refer to the BCT's taxonomy cluster)). The BCT taxonomy has been used to code the content of interventions across a range of health behaviours including medication adherence.[@R14]

The BCT content of each intervention was rated by two researchers (JC and LA). Intervention data were sourced from each published manuscript and relevant supporting documents (ie, study protocols, intervention manuals). The researchers initially rated the interventions independently and then met to discuss. BCT content was scrutinised until consensus was met between researchers.

Results {#s3}
=======

Selection process {#s3a}
-----------------

Our comprehensive search strategy identified 6072 records that were initially screened based on their title and abstract (see [figure 1](#F1){ref-type="fig"}). A total of 5874 records were excluded, leaving 198 records to be full-text screened. Twenty-seven studies[@R22] met our eligibility criteria, which comprised 23 primary studies (4 secondary studies[@R37]) (for full reason for exclusion list, see online [supplementary material](#SP1){ref-type="supplementary-material"}). Only primary study data (k*=*23, n=9735) will be discussed in the following sections.

![Preferred Reporting Items for Systematic reviews and Meta-Analysis flow diagram showing the study selection process. ACS, acute coronary syndrome; ASSIA, Applied Social Sciences Index and Abstracts; CINAHL, Cumulative Index to Nursing and Allied Health Literature; HCP, healthcare provider; PQDT, ProQuest Dissertations & Theses.](openhrt-2017-000685f01){#F1}

Study characteristics {#s3b}
---------------------

Full details of the included studies can be found in [table 3](#T3){ref-type="table"}. The majority of interventions included nurses in their delivery (k*=*13[@R23]). Six interventions were led by pharmacists (k*=*6[@R22]), and two were delivered by physicians (k*=*2[@R25]). Physiotherapists,[@R44] problem-solving therapists[@R34] and community health workers[@R46] acted as interventionists in singular trials. Nine studies were delivered exclusively in person (k*=*9[@R24]), while 10 studies included both in person and phone contact (k*=*10[@R22]). Just four study interventions were delivered exclusively by phone (k*=*4[@R25]), while six included a face-to-face predischarge component (k*=*6[@R22]). The number of intervention sessions ranged from 1[@R28] to 24[@R26] (k*=*21; median=4.0, SD=6.0). A total of 10 studies followed patients up for either 6 (k*=*5[@R22]) or 12 months (k*=*5[@R29]) (k*=*23; median=6.0 months, SD=10.3 months). Adherence to medication was a primary outcome in 14 studies (k*=*14[@R22]) and was measured exclusively by self-report in 16 studies (k*=*16[@R23]). Five studies used pharmacy data or pill counts (k*=*5[@R30]), and just two studies used both self-report and pharmacy data to measure adherence (k*=*2[@R22]).

###### 

Data extraction for all intervention studies identified in the systematic review process (k=27)

  Author                         Study details   Participant characteristics                                                                                                               
  ------------------------------ --------------- ----------------------------- ------------------------- ------ -------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Calvert *et al* [@R22]         2012            USA                           RCT, multi-site (n=2)     143    Median age: IG=63, CG=62; male: IG=66%, CG=61%; White: IG=51%, CG=51%      Usual care: routine discharge counselling and discharge summary sent to community physician.
  Cossette *et al* [@R23]        2012            Canada                        RCT, single site          242    Mean age: IG=59, CG=59; male: IG=81%, CG=90%                               Usual care: received standard predischarge care. Encouraged to use regular healthcare resources postdischarge.
  Costa e Silva *et al* [@R24]   2008            Brazil                        RCT, single site          153    Mean age: IG=58, CG=59; male: IG=63%, CG=64%                               Usual care: standard outpatient follow-up with a cardiologist.
  Du *et al* [@R25]              2016            China                         RCT, single site          979    Mean age: IG=60, CG=62; male: IG=73%, CG=72%                               Usual care: standard follow-up with research nurse.
  Giallauria *et al* [@R26]      2009            Italy                         RCT, single site          52     Mean age: IG=58, CG=57; male: IG=85%, CG=85%                               Usual care: following standard 3-month cardiac rehab, patients were discharged with usual routine recommendations and were seen only at the 12-month and 24-month follow-up.
  Giannuzzi *et al* [@R27]       2008            Italy                         RCT, multi-site (n=78)    3241   Mean age: IG=58, CG=58; male: IG=86%, CG=87%                               Usual care: a letter sent to the family physician recommending secondary prevention goals followed by standard cardiac rehab and follow-up.
  Gould[@R28]                    2011            USA                           RCT, single site          129    NR                                                                         Usual care: patients received routine discharge materials and usual care.
  Gujral *et al* [@R29]          2014            Australia                     RCT, single site          200    Mean age: IG=58, CG=60; male: IG=77%, CG=80%                               Usual care: medication beliefs not communicated to their community pharmacist. The community pharmacists were asked to provide the patient with usual care when they collected their prescription medications.
  Ho *et al* [@R30]              2014            USA                           RCT, multi-site (n=4)     253    Mean age: IG=64, CG=64; male: IG=98%, CG=98%; White: IG=82%, CG=75%        Usual care: patients received standard ACS hospital discharge instructions, a discharge medication list and educational information about cardiac medications. A 12-month clinic visit was scheduled.
  Jalal *et al* [@R32]           2016            UK                            RCT, single site          71     Mean age=NR; male=76%                                                      Usual care: following predischarge counselling from the hospital pharmacist, patients refilled their prescriptions at their usual pharmacies.
  Jorstad *et al* [@R31]         2013            Netherlands                   RCT, multi-site (n=11)    733    Mean age: IG=58, CG=58; male: IG=80%, CG=80%                               Usual care: outpatient clinic visits to treating cardiologists and other relevant specialists. Patients were referred to cardiac rehab according to national guidelines.
  Kotowycz *et al* [@R33]        2010            Canada                        RCT, single site          54     Mean age: IG=56, CG=55; male: IG=81%, CG=70%                               All discharge planning and follow-up were left to the treating physician and nursing team.
  Kronish *et al* [@R34]         2012            USA                           RCT, multi-site (n=5)     177    Mean age: IG=59, CG=61; male: IG=46%, CG=47%                               Usual care: treating physicians notified about their patients' depressive status. Patients given appropriate care for depressive symptoms.
  Lapointe *et al* [@R35]        2006            Canada                        RCT, single site          127    Mean age: IG=58, CG=57; male: IG=89%, CG=78%                               Standard follow-up with patients' regular physician.
  Miller *et al* [@R36]          1988            USA                           RCT, multi-site (n=3)     103    Mean age=NR (range 30 - 65); male: IG=73%, CG=89%; White: IG=98%, CG=87%   Usual care: all patients had received standard inpatient cardiac rehab.
  Miller *et al* [@R37]          1989            USA                           RCT, multi-site (n=3)     81     Mean age=54; male=81%                                                      Usual care: all patients had received standard inpatient cardiac rehab.
  Miller *et al* [@R38]          1990            USA                           RCT, multi-site (n=3)     51     Mean age=55; male=76%                                                      Usual care: all patients had received standard inpatient cardiac rehab.
  Muñiz *et al* [@R39]           2010            Spain                         RCT, multi-site (n=64)    1757   Mean age: IG=62, CG=64; male: IG=78%, CG=76%                               Usual care.
  Najafi *et al* [@R40]          2016            Iran                          RCT, single site          100    Mean age: IG=59, CG=58; male: IG=54%, CG=38%                               Routine care including check-ups with designated physician.
  Polack *et al* [@R41]          2008            Canada                        RCT, single site          10     Mean age: IG=59, CG=65; male: IG=80%, CG=100%                              Usual care: standard predischarge nurse education.
  Polsook *et al* [@R42]         2016            Thailand                      RCT, single site          44     Mean age: IG=61, CG=63; male: IG=86%, CG=86%                               Usual care in the cardiac inpatient department that included education about patients' condition and treatment.
  Redfern *et al* [@R44]         2008            Australia                     RCT, single site          144    Mean age: IG=62, CG=67; male: IG=74%, CG=75%                               Ongoing conventional care determined by patients' family physician and cardiologist.
  Redfern *et al* [@R43]         2009            Australia                     RCT, single site          144    Mean age: IG=62, CG=67; male: IG=74%, CG=75%                               Usual care: received medical treatment, including pharmacotherapy and lifestyle counselling, as determined by their usual doctors.
  Uysal and Ozcan[@R45]          2015            Turkey                        RCT, multi-site (n*=*2)   90     Mean age=NR (47% between 45-54); male: IG=80%, CG=76%                      Received home education kit comprised of brochures about healthy living post-MI. Not provided with telephone counselling and education.
  Xavier *et al* [@R46]          2016            India                         RCT, multi-site (n=14)    806    Mean age: IG=56, CG=57; male: IG=82%, CG=83%                               Standard care: patients were asked to alert the research team to any hospital visits that they planned.
  Sharma *et al* [@R47]          2016            India                         RCT, single site          100    Mean age: IG=57, Con=61; Male total=84%                                    Usual care.
  Yorio *et al* [@R48]           2008            USA                           RCT, single site          144    Median age: IG=56, CG=56; male: IG=67%, CG=57%; White: IG=32%, CG=35%      Usual care: standard postdischarge care that included appointments with a cardiologist and family physician within 3 months.

  Author                         Methodological features                                                                                                                                                           
  ------------------------------ ------------------------- ----------- ------------------ --------------------------------------------------------------------------------------------- -------------------------- ----
  Calvert *et al* [@R22]         Not stated                6 months    Primary            Medication adherence                                                                          Self-report; MMAS-4; PDC   4
  Cossette *et al* [@R23]        Not stated                6 weeks     Secondary          Cardiac rehab attendance                                                                      MMAS-4                     3
  Costa e Silva *et al* [@R24]   Yes                       6 months    Primary (one of)   Clinical improvement index (including medication adherence)                                   Self-report                2
  Du *et al* [@R25]              Not stated                36 months   Secondary          Mortality and MACE                                                                            MMAS-4                     6
  Giallauria *et al* [@R26]      Not stated                24 months   Secondary          Cardiopulmonary parameters and cardiovascular risk profile (including medication adherence)   Self-report                24
  Giannuzzi *et al* [@R27]       Yes                       36 months   Secondary          MACE                                                                                          Self-report                11
  Gould[@R28]                    Not stated                3 days      Primary (one of)   Medication adherence, use of urgent care, patient satisfaction and illness perceptions        MMAS-4                     1
  Gujral *et al* [@R29]          Not stated                12 months   Primary (one of)   Medication adherence and treatment beliefs                                                    MARS; MPR                  2
  Ho *et al* [@R30]              Yes                       12 months   Primary            Medication adherence                                                                          PDC                        4
  Jalal *et al* [@R32]           Not stated                6 months    Primary            Medication adherence                                                                          MMAS-8                     1
  Jorstad *et al* [@R31]         Not stated                12 months   Secondary          Lifestyle and biometric targets                                                               Self-report                4
  Kotowycz *et al* [@R33]        Yes                       6 weeks     Secondary          MACE                                                                                          Self-report                4
  Kronish *et al* [@R34]         Yes                       6 months    Primary (one of)   Adherence to medication, heart healthy diet, regular exercise and smoking cessation           Self-report                NR
  Lapointe *et al* [@R35]        Not stated                18 months   Secondary          LDL-C targets                                                                                 Prescription refills       NR
  Miller *et al* [@R36]          Not stated                60 days     Primary            MRA                                                                                           HBS                        3
  Miller *et al* [@R37]          Not stated                12 months   Primary            MRA                                                                                           HBS                        3
  Miller *et al* [@R38]          Not stated                24 months   Primary            MRA                                                                                           HBS                        3
  Muñiz *et al* [@R39]           Not stated                6 months    Primary (one of)   Behavioural and clinical targets (including medication adherence)                             Self-report                2
  Najafi *et al* [@R40]          Not stated                3 months    Primary            Medication adherence                                                                          MMAS-8                     6
  Polack *et al* [@R41]          Not stated                6 weeks     Primary (one of)   Medication adherence and knowledge retention                                                  MMAS-4                     2
  Polsook *et al* [@R42]         Not stated                4 weeks     Primary (one of)   Medication adherence and self-efficacy                                                        Pill count                 14
  Redfern *et al* [@R43]         Yes                       3 months    Secondary          Behavioural and clinical targets                                                              Self-report                5
  Redfern *et al* [@R44]         Yes                       12 months   Secondary          Behavioural and clinical targets                                                              Self-report                5
  Uysal and Ozcan[@R45]          Not stated                3 months    Primary (one of)   Physical activity, medication adherence, anginal symptoms                                     MMAS-4                     3
  Xavier *et al* [@R46]          Yes                       12 months   Primary            Medication adherence                                                                          CMAS                       18
  Sharma *et al* [@R47]          Yes                       24 months   Primary            Mediation adherence                                                                           CMAS                       10
  Yorio *et al* [@R48]           Not stated                12 months   Secondary          Improved LDL-C profile                                                                        Prescription refills       1

  Author                         Intervention features                                                  
  ------------------------------ ----------------------------------- --------------------- ------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Calvert *et al* [@R22]         Pharmacist                          In person and phone   Not stated   Predischarge counselling covering the importance and purpose of medications and barriers to adherence. Pocket medication card, cheat sheet (tips for remembering) and pillbox also provided. Regular follow-up with community pharmacist to discuss adherence-related issues.
  Cossette *et al* [@R23]        Nurse                               In person and phone   CS-SRM       Predischarge counselling session: symptom and physical activity management, coherence around illness episode, concerns/worries. Postdischarge counselling sessions: disease management, concerns/worries and intentions about risk factor modification, problem solving.
  Costa e Silva *et al* [@R24]   MDT (included nurse)                In person only        Not stated   Transdisciplinary outpatient care provided. Detailed treatment planning and follow-up with nurse, dietitian, endocrinologist and cardiologist. HCPs collaborated to reinforce lifestyle change and formulate a care plan.
  Du *et al* [@R25]              Physician (cardiologist)            Phone only            Not stated   Physician-led intensive telephone follow-up over 36 months. Patients provided with additional health education, disease-prevention suggestions and consultations on medication usage. Face-to-face visits were scheduled if necessary.
  Giallauria *et al* [@R26]      MDT (included nurse)                In person only        Not stated   Monthly hospital meetings to discuss lifestyle change and engage in exercise training. Received a booklet about lifestyle change and promoting patients' role in their healthcare. Encouraged family support throughout.
  Giannuzzi *et al* [@R27]       MDT (included nurse)                In person only        Not stated   Comprehensive cardiac rehab sessions that included exercise training and lifestyle and risk factor counselling. Encouraged family support throughout. Pharmacological treatments positively recommended to all patients. Received booklet to support lifestyle change and patient empowerment.
  Gould[@R28]                    Nurse                               Phone only            CS-SRM       Patients received written discharge materials, telephone follow-up by an expert, medication review materials, a medication pocket card and suggested websites.
  Gujral *et al* [@R29]          Pharmacist                          In person and phone   NCF          Tailored intervention targeting treatment beliefs. Beliefs and attitudes towards treatment elicited using repertory grid technique and then communicated to the community pharmacist. Information used to tailor their discussions with the patient during follow-up. Patient also reviewed monthly by community pharmacist to discuss adherence-related issues.
  Ho *et al* [@R30]              Pharmacist                          In person and phone   Not stated   Pharmacist-led postdischarge medication reconciliation and follow-up. Predischarge and postdischarge education sessions with pharmacist followed by automated educational voice messages. Use of pill boxes to organise medications. Increased communication between pharmacists and patients' care team. Automated voice reminders to refill prescriptions.
  Jalal *et al* [@R32]           Pharmacist                          In person and phone   Not stated   Community pharmacist-led motivational interview aimed at improving protective cardiovascular medicine taking. Consultations were delivered as part of the New Medicine Service or a Medication Usage Review (established UK NHS pharmacy services).
  Jorstad *et al* [@R31]         Nurse                               In person only        Not stated   Outpatient visits with a nurse: educational sessions targeted lifestyle change and risk factor management. Lifestyle and risk factors reviewed and patients received individual counselling. Medication adherence encouraged and reasons for discontinuation discussed.
  Kotowycz *et al* [@R33]        Nurse                               In person and phone   Not stated   Nurse-led patient education about the nature and management of their cardiac disease, with a focus on medications and facilitation of discharge planning.
  Kronish *et al* [@R34]         Other (problem-solving therapist)   In person only        Not stated   Patients given a choice of either PST and/or pharmacotherapy. Weekly PST sessions were brief, problem focused and designed to augment self-efficacy and address psychosocial issues. Focus also on the initiation of pleasant activities. Patients given choice of different pharmacotherapy.
  Lapointe *et al* [@R35]        Nurse                               Phone only            Not stated   Patients received postdischarge letter and phone call concerning risk factor education and management. Clinical goals (lipid profile) set and patients received additional intervention from their physician if goals not met. Compliance assessment with pharmacist conducted at 12 and 18 months.
  Miller *et al* [@R36]          Nurse                               In person only        TRA          Intervention included an assessment (addressing attitudes, beliefs and intentions), problem identification (coping and societal adjustment) and developing a detailed health plan. Spouses were encouraged to participate.
  Miller *et al* [@R37]          Nurse                               In person only        TRA          Intervention included an assessment (addressing attitudes, beliefs and intentions), problem identification (coping and societal adjustment) and developing a detailed health plan. Spouses were encouraged to participate.
  Miller *et al* [@R38]          Nurse                               In person only        TRA          Intervention included an assessment (addressing attitudes, beliefs and intentions), problem identification (coping and societal adjustment) and developing a detailed health plan. Spouses were encouraged to participate.
  Muniz *et al* [@R39]           Physician                           In person only        Not stated   Focused on the patient-provided relationship. Discharge interview included a signed agreement of secondary prevention care plan and comprehensive written material about risk factor management. During a follow-up session, agreement reviewed and adapted if necessary.
  Najafi *et al* [@R40]          Researcher (nurse)                  Phone only            Not stated   Nurse-led follow-up telephone calls based on lifestyle counselling and education. Agreed behavioural objectives were reviewed and barriers were addressed through problem solving. Family participation was encouraged throughout.
  Polack *et al* [@R41]          Pharmacist                          In person only        Not stated   Received predischarge pharmacist-led education around the benefits and risks of cardiac medications. Sessions included use of a patient education tool.
  Polsook *et al* [@R42]         Researcher (nurse)                  In person and phone   Not stated   Comprised a 4-week self-efficacy enhancement program that targeted patients' motivation to be adherent, skills development and adherence self-monitoring.
  Redfern *et al* [@R43]         Other (physiotherapist)             In person and phone   Not stated   Based around risk factor assessment and goal setting. Patients chose their risk factor module and self-committed to a written action plan. Received a resource pack that included information leaflets. Follow-up sessions tested patients' knowledge of their risk factors. Personal goals were also identified and positive. Risk-lowering behaviour recorded.
  Redfern *et al* [@R44]         Other (physiotherapist)             In person and phone   Not stated   Based around risk factor assessment and goal setting. Patients chose their risk factor module and self-committed to a written action plan. Received a resource pack that included information leaflets. Follow-up sessions tested patients' knowledge of their risk factors. Personal goals were also identified and positive. Risk-lowering behaviour recorded.
  Uysal and Ozcan[@R45]          Researcher (nurse)                  In person and phone   Not stated   Individualised education plans around lifestyle and risk factor management. Received access to a computer-based education along with brochures on lifestyle changes post-MI. Telephone counselling during follow-up addressing negative health behaviours, including treatment non-adherence.
  Xavier *et al* [@R46]          Other: community health worker      In person and phone   Not stated   Involved personalised counselling to help overcome barriers to adherence and lifestyle modification. Also received an adherence calendar to record medication taking and were asked to complete diaries, which included information about their medications. Family participation encouraged.
  Sharma *et al* [@R47]          Other: community health worker      In person and phone   Not stated   Involved personalised counselling to help overcome barriers to adherence and lifestyle modification. Also received an adherence calendar to record medication taking and were asked to complete diaries, which included information about their medications. Family participation encouraged.
  Yorio *et al* [@R48]           Nurse or pharmacist                 In person only        Not stated   Postdischarge session with nurse or pharmacist. Session included full medication review and titration, risk factor counselling and discussion/referral to cardiac rehab and other HCPs (dietician and/or smoking cessation service).

ACS, acute coronary syndrome; CG, control group; CMAS, Composite Medication Adherence Score; CS-SRM, Common-Sense Model of Self-Regulation; HBS, Health Behaviour Scale; HCP, healthcare provider; IG, intervention group; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiac events; MARS, Medication Adherence Report Scale; MDT, multidisciplinary team; MI, myocardial infarction; MMAS-4, Morisky Medication Adherence Scale (4-item); MMAS-8, Morisky Medication Adherence Scale (8-item); MPR, medication possession ratio; MRA, medical regimen adherence; NCF, necessity concerns framework; NR, not reported; PDC, proportion of days covered; PST, problem-solving therapy; RCT, randomised controlled trial; TRA, theory of reasoned action.

Risk of bias {#s3c}
------------

A summary of the risk of bias assessment can be seen in [figure 2](#F2){ref-type="fig"}. All but one of the studies[@R31] were rated as having 'unclear' risk of performance bias due to the impracticality of blinding participants and personnel to group allocation during behavioural studies. 'High' risk of detection bias was judged in nine studies that did not adopt end-point blinding (k*=*9[@R24]). After excluding performance bias ratings, six studies were judged to have 'low' risk of bias across all other domains (k*=*6[@R22]). Three of these 'low-risk' studies were delivered by pharmacists (k*=*3[@R22]), and the rest were led by nurses,[@R27] physiotherapists[@R44] or problem-solving therapists.[@R34] Trials with the smallest[@R41] and largest sample sizes[@R27] were among the 'low risk'-rated studies, and all six were either delivered exclusively in person (k*=*3[@R27]) or in person with phone contact (k*=*3[@R22]) (for complete risk of bias assessment, see online [supplementary material](#SP1){ref-type="supplementary-material"}).

![Risk of bias assessment.](openhrt-2017-000685f02){#F2}

BCT inclusion {#s3d}
-------------

[Figure 3](#F3){ref-type="fig"} shows the frequency of BCTs coded across studies. None of the studies referenced the BCT taxonomy in their intervention design. A total of 32 (34%) of the 93 BCTs listed in the taxonomy were identified among studies, ranging between 1[@R28] and 10[@R44] (mean=4.7, SD=2.2). 'Information about health consequences' (BCT 5.1) was the most commonly identified BCT, coded in 19 of the 23 studies. 'Social support (unspecified)' (BCT 3.1) was coded in seven studies, and 'action planning' (BCT 1.4) was identified in just two studies.[@R32] There were six instances of 'goal setting (outcome)' (BCT 1.3), 'monitoring of behaviour by others without feedback' (BCT 2.1), 'feedback on outcome(s) of behaviour' (BCT 2.7) and 'instruction on how to perform the behaviour' (BCT 4.1) across studies. Around two-thirds (67%) of the total number of BCTs coded were from just three taxonomy clusters: goals and planning (cluster 1, n=26 (24%)), natural consequences (cluster 5, n=25 (23%)) and feedback and monitoring (cluster 2, n=21 (20%)). There were no BCTs coded from three taxonomy clusters: reward and threat (cluster 10), scheduled consequences (cluster 14) and covert learning (cluster 16). There were no instances where every BCT in a cluster was coded (goals and planning: cluster 1, 8/9 BCTs coded; feedback and monitoring: cluster 2, 6/7 BCTs coded).

![Frequency of BCTs identified among interventions. BCT, behaviour change technique.](openhrt-2017-000685f03){#F3}

Meta-analysis {#s3e}
-------------

A random-effects meta-analysis of 23 primary studies (n=9735) revealed that HCP-led interventions increased the odds of medication adherence by 54% compared with control interventions with moderate to high statistical heterogeneity (k*=*23, OR 1.54, 95% CI 1.26 to 1.88 (I^2^=57.5%, P=0.001)) (see [figure 4](#F4){ref-type="fig"}). After removing two outliers,[@R40] a meta-analysis of 9545 patients indicated that HCP-led interventions increased the odds of medication adherence by 41% compared with control interventions with moderate statistical heterogeneity (k*=*21, OR 1.41, 95% CI 1.21 to 1.65 (I^2^=35.3%, P=0.057)) (see [figure 5](#F5){ref-type="fig"}). While Egger's test was non-significant (P=0.286), visual inspection of the funnel plot suggests a potential bias even after discounting outliers (for funnel plot, see online [supplementary material](#SP1){ref-type="supplementary-material"}).

![Forest plot showing pooled effects size for healthcare-provider-led interventions on medication adherence (k=23, includes outliers).](openhrt-2017-000685f04){#F4}

![Forest plot showing pooled effects size for healthcare-provider-led interventions on medication adherence (k=21, outliers removed).](openhrt-2017-000685f05){#F5}

Subgroup analyses {#s3f}
-----------------

[Table 4](#T4){ref-type="table"} shows the results of our prespecified (ie, interventionist, delivery method, theoretical basis) and post hoc (ie, adherence outcome, risk of bias) subgroup analyses. The largest effect sizes were for interventions that included phone contact (k*=*12, OR 1.63, 95% CI 1.25 to 2.12), and there was a trend for better-quality studies (ie, 'low' risk of bias) to increase the odds of adherence (k*=*6, OR 1.69, 95% CI 1.15 to 2.47). A negligible positive effect was found for interventions delivered by nurses (k*=*11, OR 1.19, 95% CI 1.04 to 1.36), and pharmacist-led interventions had a small though non-significant effect on medication adherence (k*=*6, OR 1.44, 95% CI 0.92 to 2.26). Studies led by HCPs other than nurses and pharmacists (ie, physicians,[@R25] physiotherapists,[@R44] problem-solving therapists,[@R34] community health workers[@R46]) yielded a small positive effect on medication adherence (k*=*5, OR 1.66, 95% CI 1.22 to 2.24). We found no discernible differences in effect size between studies that included adherence as a primary or secondary outcome, and a small number of theoretically informed studies had a non-significant trend towards a negative effect on adherence (k*=*4, OR 0.94, 95% CI 0.60 to 1.49).

###### 

Overall effects and subgroup analyses for medication adherence interventions

                            **k**   **N**   **OR**   **CI**         **I² (%)**   **P heterogeneity**   **P bias**
  ------------------------- ------- ------- -------- -------------- ------------ --------------------- ------------
  Overall                                                                                              
   All studies              23      9735    1.54     1.26 to 1.88   57.5         0.001                 0.066
   Excluding outliers       21      9545    1.41     1.21 to 1.65   35.3         0.057                 0.286
  Interventionist                                                                                      
   Pharmacist               6       813     1.44     0.92 to 2.26   30.0         0.210                 0.309
   No pharmacist            15      8732    1.41     1.19 to 1.68   41.0         0.049                 0.439
   Nurse                    11      5030    1.19     1.04 to 1.36   0            0.920                 0.501
   No nurse                 10      4515    1.63     1.26 to 2.10   52.1         0.027                 0.454
   Other HCPs               5       3842    1.66     1.22 to 2.24   67.1         0.012                 0.550
   Nurse or pharmacists     16      5703    1.21     1.07 to 1.38   0            0.663                 0.167
  Delivery method                                                                                      
   In person only           9       6358    1.21     1.08 to 1.36   0            0.890                 0.305
   Included phone contact   12      3187    1.63     1.25 to 2.12   32.0         0.135                 0.629
  Theoretical basis                                                                                    
   Theory based             4       686     0.94     0.60 to 1.49   0            0.781                 0.692
   Not theory based         17      8859    1.48     1.25 to 1.76   41.4         0.038                 0.094
  Outcome                                                                                              
   Primary                  12      3833    1.31     1.11 to 1.54   0            0.622                 0.227
   Secondary                9       5712    1.48     1.12 to 1.96   63.1         0.006                 0.548
  Risk of bias                                                                                         
   Low risk                 6       3948    1.69     1.15 to 2.47   51.4         0.068                 0.042
   Higher risk              15      5597    1.36     1.13 to 1.64   28.1         0.147                 0.658

HCP, healthcare provider; I², heterogeneity; k, number of studies; N, sample size; P bias, small study effects significance; P heterogeneity, heterogeneity significance.

Interventionist, delivery method and theoretical basis were prespecified subgroups, while outcome and risk of bias were determined post hoc. Outliers were excluded from subgroup analyses.[@R40]

Discussion {#s4}
==========

The primary objective of this study was to identify interventions led by HCPs to improve medication adherence following ACS. Meta-analysis revealed a small effect of HCP-led interventions on medication adherence. Our results are consistent with previous meta-analysis studies that have looked at the effectiveness of adherence interventions in other cardiac patient populations.[@R5]

In line with recent adherence literature,[@R49] the majority of intervention studies identified were delivered by nurses or pharmacists. However, we found no indication that study effectiveness was moderated by the HCP delivering the intervention. Studies that included nurses in their delivery had a negligible effect towards better medication adherence, which does not correspond to findings from another meta-analysis that found that nurse-led interventions had a small to medium effect on adherence in patients with CAD.[@R5] Six pharmacist-led interventions had a small but non-significant effect on medication adherence, which is congruous with previous reviews across cardiac-related diseases.[@R5] Objectively, pharmacists should be ideal candidates to deliver adherence interventions due to the necessary knowledge and skills they possess to promote and support medication-taking behaviour.[@R50] A meta-analysis of 771 medication adherence intervention trials found that the most effective interventions were delivered by pharmacists,[@R49] which suggests that pharmacists may be better utilsied in other patient populations. Our findings should, however, be interpreted with caution due to the small number of pharmacist-led studies included in our analyses.

In terms of delivery method, interventions that included phone contact had higher odds of medication adherence compared with interventions delivered exclusively in person. Phone-delivered interventions may be a more convenient method to reach patients after discharge to monitor and encourage good medication adherence over time. Half of the interventions that included phone contact also contained a face-to-face predischarge component. Cutrona *et al* [@R51] found that two-thirds of interventions delivered at discharge were effective at improving adherence to cardiovascular medicines. Periods of care transition such as during hospital discharge are ideal opportunities to discuss treatment to pre-empt potential barriers to regimen adherence. Moreover, the dynamic nature of adherence dictates that monitoring of medication-taking behaviour over time by both patients and/or HCPs is crucial to ensure therapy maintenance for long-term conditions such as ACS.

We expected to find a greater proportion of interventions that used theoretical approaches to change medication-taking behaviour. There were only four studies that reported a theoretical basis, of which just one was based on a model of medication-taking behaviour (necessity--concerns framework[@R52]). A review by Conn *et al* [@R53] found that theory-driven interventions had a significant but modest effect on medication adherence. Our findings suggest that theory-driven adherence interventions for ACS are lacking, thus highlighting an important avenue for future research.

Coding intervention content {#s4a}
---------------------------

To our knowledge, this review is the first to use the BCT taxonomy to code interventions that targeted adherence across all cardiac medications following ACS. The BCT taxonomy provided a useful tool to analyse the content of adherence interventions, and we found that one-third of all BCTs detailed in the taxonomy were identified in at least one intervention. This relatively small number of total BCTs identified was unsurprising as many were not applicable to medication-taking behaviour. It is likely that additional strategies may have been used among interventions but were not identified due to a lack of detail in the description of the intervention. A lack of transparency in study reporting is an issue that limits the usability and replicability of interventional research. Checklists such as TIDieR[@R54] are becoming commonplace to improve the quality of intervention reporting.

Written, verbal or visual information provision about the consequences of adherence (BCT 5.1) was by far the most frequently used BCT among HCP-led interventions. Discussing the consequences of non-adherence may help to strengthen patients' beliefs in the necessity of their medications, which have been shown to predict non-adherence.[@R55] While information is necessary to improve patients' knowledge, it is not sufficient as a standalone strategy to change behaviour. Information-only strategies have been found to be generally ineffective at changing complex behaviours such as adherence.[@R56]

Clinical and research implications {#s4b}
----------------------------------

Medication taking is a complex behaviour that can be difficult to change. Targeting patients identified with an adherence issue rather than all medication-takers may be one strategy to improve the effectiveness of adherence interventions. Cutrona *et al* [@R57] reported that 'broad' interventions (target all medication-takers) were less effective than 'focused' (target non-adherers only). None of the studies identified in this review targeted non-adherers; therefore, it is not yet known whether 'focused' interventions would be more appropriate for patients with ACS.

There were a variety of adherence measures used among included interventions, most of which were non-validated self-report tools. While an approach that combines self-reporting with an objective measure (eg, prescription refill records) is considered best practice, just two interventions followed this guidance. No studies used electronic monitors (eg, Medication Event Monitoring System) that provide real-time data on medication-taking behaviour[@R58] and have been used to good effect in studies with patients with hypertension,[@R59] heart failure[@R60] and CAD.[@R61] There is potential for objective measures to be used in conjunction with self-report tools to provide a more reliable and accurate representation of medication-taking behaviour of patients with ACS.

Strengths and limitations {#s4c}
-------------------------

The strengths of this study include the adoption of a comprehensive search strategy that comprised eight online databases and a supplementary grey literature search. Additionally, we applied an existing behaviour change framework to identify specific techniques used among HCP-led adherence interventions, which we believe is a novel approach for trials with patients with ACS. Our study does also include certain limitations. First, while we were successful in BCT identification, there were insufficient data to determine the effectiveness of particular BCTs. A larger data set would be required to undertake the type of meta-regression analyses that have recently been reported within the adherence literature.[@R62] Second, we found relatively high levels of statistical heterogeneity in our random-effects models, which is inherent when comparing methodologically diverse behavioural interventions. We accounted for this variability by removing outliers, which resulted in our final model having moderate statistical heterogeneity. Third, only one researcher was involved in all aspects of the identification, screening, data extraction and risk of bias assessments, although dual-raters coded interventions independently using the BCT taxonomy. Best practice would be to include multiple independent raters in all stages of the review to ensure methodological rigour. Fourth, we decided not to exclude studies based on how medication adherence was measured, which was often done using unreliable self-report methods. A previous review by Santo *et al* [@R63] circumvented this issue somewhat by including stricter adherence measurement eligibility criteria. Ultimately, all methods of adherence measurement are limited in terms of practicality, reliability and cost, which represents a wider issue across the adherence literature.

Conclusion {#s5}
==========

This study suggests that HCP-led interventions have a small positive effect on medication adherence following ACS. An existing BCT taxonomy was used successfully to identify common techniques within adherence interventions. However, data were insufficient to draw firm conclusions regarding the impact of BCTs on intervention effectiveness. Information provision remains the basis of most adherence interventions. Further work is required to understand how intervention design and delivery determines the effectiveness of adherence interventions following ACS.
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